Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Feb 9, 2026 · 10-Q · 40 days after period end · 0001731122-26-000200
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$5.68M | -$12.11M | -$8.62M | -$12.97M |
| EPS Diluted | -$0.06 | -$0.14 | -$0.11 | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Feb 9, 2026 · 40 d after period end
